Key result
Fucoxanthin alleviates myocardial ischemia-reperfusion injury by inhibiting ferroptosis via the NRF2 pathway.
Why the study?
Myocardial ischemia and reperfusion injury is a severe complication of revascularization therapy with limited therapeutic options, and ferroptosis is a critical contributor to this injury.
Does fucoxanthin alleviate myocardial ischemia and reperfusion injury in preclinical models?
Does fucoxanthin alleviate myocardial ischemia and reperfusion injury in preclinical models?
Answers are grounded in this paper and cite their sources.
Fucoxanthin exerts cardioprotective effects against myocardial ischemia and reperfusion injury by inhibiting ferroptosis through the NRF2 signaling pathway in preclinical models.
Background: Myocardial ischemia and reperfusion injury (MIRI) is a severe complication of revascularization therapy in patients with myocardial infarction. Therefore, there is an urgent requirement to find more therapeutic solutions for MIRI. Recently, ferroptosis, which is characterized by lipid peroxidation, was considered a critical contributor to MIRI. Fucoxanthin (FX), a natural antioxidant carotenoid, which is abundant in brown seaweed, exerts protective effects under various pathological conditions. However, whether FX alleviates MIRI is unclear. This study aims to clarify the effects of FX on MIRI. Methods: Mice with left anterior descending artery ligation and reperfusion were used as in vivo models. Neonatal rat cardiomyocytes (NRCs) induced with hypoxia and reperfusion were used as in vitro models. TTC-Evans blue staining was performed to validate the infarction size. Transmission electron microscopy was employed to detect mitochondrial injury in cardiomyocytes. In addition, 4 weeks after MIRI, echocardiography was performed to measure cardiac function; fluorescent probes and western blots were used to detect ferroptosis. Results: TTC-Evans blue staining showed that FX reduced the infarction size induced by MIRI. Transmission electron microscopy showed that FX ameliorated the MIRI-induced myofibril loss and mitochondrion shrinkage. Furthermore, FX improved LVEF and LVFS and inhibited myocardial hypertrophy and fibrosis after 4 weeks in mice with MIRI. In the in vitro study, calcein AM/PI staining and TUNEL staining showed that FX reduced cell death caused by hypoxia and reperfusion treatment. DCFH-DA and MitoSOX probes indicated that FX inhibited cellular and mitochondrial reactive oxygen species (ROS). Moreover, C11-BODIPY 581/591 staining, ferro-orange staining, MDA assay, Fe2+ assay, 4-hydroxynonenal enzyme-linked immunosorbent assay, and western blot were performed and the results revealed that FX ameliorated ferroptosis in vitro and in vivo, as indicated by inhibiting lipid ROS and Fe2+ release, as well as by modulating ferroptosis hallmark FTH, TFRC, and GPX4 expression. Additionally, the protective effects of FX were eliminated by the NRF2 inhibitor brusatol, as observed from western blotting, C11-BODIPY 581/591 staining, and calcein AM/PI staining, indicating that FX exerted cardio-protective effects on MIRI through the NRF2 pathway. Conclusion: Our study showed that FX alleviated MIRI through the inhibition of ferroptosis via the NRF2 signaling pathway.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2023) studied Myocardial ischemia and reperfusion injury (MIRI). Fucoxanthin was evaluated on Infarction size, cardiac function, and ferroptosis. Fucoxanthin alleviated myocardial ischemia and reperfusion injury in mice and cardiomyocytes by reducing infarction size and inhibiting ferroptosis via the NRF2 signaling pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: